Compare Gilead Sciences, Inc. (GILD) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Gilead Sciences, Inc. trades at $135.44 (market cap $163.51B), while YieldMax MSTR Option Income Strategy ETF trades at $12.78. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while YieldMax MSTR Option Income Strategy ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| GILD | MSTY | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $155.80 | $114.30 |
52-Week Low | $108.22 | $11.55 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
MSTY trades at $12.75, down 3.41% today amid bearish technical signals. The ETF shows consistent weekly dividend distributions but faces significant price erosion, with technical indicators showing bearish moving averages and neutral oscillators. Recent news highlights concerns about uncapped losses despite high distributions, with the fund experiencing substantial NAV decline over the past year.
The outlook remains challenging as MSTY's high-yield strategy comes with structural risks including return of capital distributions and capped upside potential. Investors face the dual risk of NAV erosion and dependency on Bitcoin-related volatility, requiring careful assessment of total return potential versus income generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
